152 related articles for article (PubMed ID: 37184753)
1. Cipaglucosidase Alfa: First Approval.
Blair HA
Drugs; 2023 Jun; 83(8):739-745. PubMed ID: 37184753
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
[TBL] [Abstract][Full Text] [Related]
3. Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease.
Fiege L; Duran I; Marquardt T
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765007
[TBL] [Abstract][Full Text] [Related]
4. Avalglucosidase alfa: First Approval.
Dhillon S
Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
[TBL] [Abstract][Full Text] [Related]
5. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B; Kishnani PS; Bratkovic D; Byrne BJ; Claeys KG; Díaz-Manera J; Laforêt P; Roberts M; Toscano A; van der Ploeg AT; Castelli J; Goldman M; Holdbrook F; Sitaraman Das S; Wasfi Y; Mozaffar T;
J Neurol; 2024 May; 271(5):2810-2823. PubMed ID: 38418563
[TBL] [Abstract][Full Text] [Related]
6. The new horizons for treatment of Late-Onset Pompe Disease (LOPD).
Guémy C; Laforêt P
Rev Neurol (Paris); 2023; 179(1-2):81-89. PubMed ID: 36609019
[TBL] [Abstract][Full Text] [Related]
7. Improved efficacy of a next-generation ERT in murine Pompe disease.
Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Byrne BJ; Schoser B; Kishnani PS; Bratkovic D; Clemens PR; Goker-Alpan O; Ming X; Roberts M; Vorgerd M; Sivakumar K; van der Ploeg AT; Goldman M; Wright J; Holdbrook F; Jain V; Benjamin ER; Johnson F; Das SS; Wasfi Y; Mozaffar T
J Neurol; 2024 Apr; 271(4):1787-1801. PubMed ID: 38057636
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
[TBL] [Abstract][Full Text] [Related]
10. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
[TBL] [Abstract][Full Text] [Related]
11. Response to Comments on "Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice".
George K; Anding A
J Pharmacol Exp Ther; 2024 May; 389(3):313-314. PubMed ID: 38772716
[TBL] [Abstract][Full Text] [Related]
12. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
Dimachkie MM; Barohn RJ; Byrne B; Goker-Alpan O; Kishnani PS; Ladha S; Laforêt P; Mengel KE; Peña LDM; Sacconi S; Straub V; Trivedi J; Van Damme P; van der Ploeg AT; Vissing J; Young P; Haack KA; Foster M; Gilbert JM; Miossec P; Vitse O; Zhou T; Schoser B;
Neurology; 2022 Aug; 99(5):e536-e548. PubMed ID: 35618441
[TBL] [Abstract][Full Text] [Related]
13. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
14. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
17. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
[TBL] [Abstract][Full Text] [Related]
18. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
20. Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice.
Anding A; Kinton S; Baranowski K; Brezzani A; De Busser H; Dufault MR; Finn P; Keefe K; Tetrault T; Li Y; Qiu W; Raes K; Vitse O; Zhang M; Ziegler R; Sardi SP; Hunter B; George K
J Pharmacol Exp Ther; 2023 Nov; 387(2):188-203. PubMed ID: 37679046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
